GROWTH FACTORS are critical modulators of the kidney's response to all forms of injury. After renal injury, growth factors are upregulated and coordinate cellular events, such as dedifferentiation, migration, and proliferation, that lead to repair. In the injured kidney, growth factors affect the responses of the injured epithelium, surrounding fibroblasts, endothelium, and infiltrating inflammatory cells, and the balance of these growth factors impacts how the kidney recovers. Two growth factors that play key roles in the response to injury are hepatocyte growth factor (HGF) and transforming growth factor-␤ (TGF-␤).
TGF-␤ and HGF signaling are increased in the damaged epithelium (15, 21) . All three TGF-␤ ligands (␤1, ␤2, and ␤3) bind to the ubiquitously expressed TGF-␤ type II receptor (T␤RII), which heterodimerizes with the type I receptor (T␤RI) and transduces intracellular signaling through canonical Smads, as well as noncanonical pathways, such as MAPK and GTPases. HGF exerts its effects through the tyrosine kinase receptor c-Met, which becomes autophosphorylated upon ligand binding and then activates intracellular signaling mediators such as ERK and phosphatidylinositol 3-kinase (30) . The diverse downstream signaling pathways of both growth factors lead to multiple cellular responses, such as cell growth and differentiation. TGF-␤ and HGF affect some of these cellular events in a similar manner, while other responses are divergent. Both growth factors promote epithelial dedifferentiation, spreading, and migration after injury: HGF has proproliferative and antiapoptotic effects on the epithelium (41) , while TGF-␤ is cytostatic and increases susceptibility to apoptosis (10) . Consistent with these findings, HGF plays a predominantly protective role in renal injury (11, 16, 21, 25) , whereas excess TGF-␤ adversely impacts renal injury (17, 18, 23) . Many studies show that TGF-␤ and HGF negatively regulate each other's production during kidney injury (8, 24) . While several investigations have focused on how TGF-␤ signaling affects HGF production, few have examined how TGF-␤ alters HGF signaling in renal epithelia, the main target of HGF in the injured kidney and a critical compartment for renal regeneration (41) .
The Notch signaling pathway, like TGF-␤ and HGF, is integral to epithelial cell differentiation and is upregulated in renal injury. In canonical mammalian Notch signaling, the Delta-like and Jagged ligands bind to one of four Notch receptors (13) . After ligand binding, ␥-secretase cleaves the Notch intracellular domain, which translocates into the nucleus and activates target genes (13) . TGF-␤ stimulates Notch activity in renal tubules, which is important in TGF-␤-mediated cell dedifferentiation (22, 37) . Although there is little information on how Notch impacts HGF signaling in the kidney, cross talk between these two signaling pathways alters the response to cardiac injury, as well as tumor development (1, 12, 38) . TGF-␤, Notch, and HGF pathways are upregulated in injured proximal tubules (PTs), but how these signaling pathways interact to alter epithelial responses is not clear.
Our group previously showed that blocking TGF-␤ signaling in PT epithelium protected against HgCl 2 -induced acute kidney injury in mice (10) . Given the antagonistic relationship between TGF-␤ and HGF described above, we hypothesized that inhibition of TGF-␤ may be protective, in part, by augmenting HGF signaling. Contrary to our expectation, we found that TGF-␤ signaling in PTs augmented responsiveness to HGF through transcriptional upregulation of c-Met. This TGF-␤-mediated increase in HGF signaling was dependent on Notch signaling. These findings elucidate novel interactions among TGF-␤, Notch, and HGF signaling pathways and suggest that blocking TGF-␤ signaling also impairs epithelial responses to HGF.
METHODS
Cell culture. PT cells were generated from the Immortomouse crossed with the Tgfbr2 flox/flox (floxed control) mouse as described previously (10) . PT cells were grown at 33°C in DMEM/F-12 medium supplemented with 2.5% FBS, hydrocortisone, insulin-transferrinselenium, triiodothyronine, and penicillin-streptomycin (complete PT medium) with interferon-␥. Prior to experiments, PT cells were moved to a 37°C environment, and interferon-␥ was removed to induce differentiation. Cortical fibroblasts were isolated from renal cortices of Tgfbr2 flox/flox mice, immortalized by transfection with pSV40 as previously described (7), and grown in DMEM/F-12 medium supplemented with 10% FBS and penicillin-streptomycin. T␤RII deletion in PT cells and cortical fibroblasts was achieved by adeno-Cre treatment in vitro as previously verified with immunoblots showing the absence of both T␤RII and response to TGF-␤1 (10, 27) .
All procedures involving mice were approved by the Animal Care and Use Committee of Vanderbilt University.
HGF stimulation. Cells were serum-starved overnight prior to treatment with HGF (40 ng/ml; Millipore). Unless otherwise noted, cells were subconfluent (Ͻ60%) at the time of HGF treatment, which lasted 20 min for all experiments. For phosphatase inhibition, PT cells were treated with 2 mM Na3VO4 30 min prior to and during HGF stimulation. For the low-calcium assay, cells were serum-starved in DMEM containing normal calcium (1 mM CaCl 2) or low calcium (5 M CaCl 2) 12 h prior to HGF treatment. To block the T␤RI, PT cells were plated with a specific ALK5 inhibitor (10 M; SB431542, Tocris Biosciences) or an equal volume of DMSO for 5 days prior to HGF stimulation. To inhibit Notch cleavage, cells were incubated with a ␥-secretase inhibitor (10 M; Selleckchem) or an equal volume of DMSO for 2 days prior to HGF stimulation.
Real-time PCR analysis. Total RNA was extracted from PT cells according to the instructions provided with the Qiagen RNeasy kit, and reverse transcription was performed using the iScript cDNA synthesis kit (Bio-Rad). Quantitative PCR (qPCR) was performed with 100 ng of cDNA, primers at 400 nM, and SYBR Green supermix (Bio-Rad) using a thermocycler (model CFX96, Bio-Rad). Relative mRNA expressions were determined by the comparative cycle threshold (⌬⌬CT) method, and, after validation with a panel of housekeeping genes, GAPDH was used as a reference gene. Primers are as follows: 5=-AGGTCGGTGTGAACGGATTTG (forward) and 5=-TGTAGACCATGTAGTTGAGGTCA (reverse) for GAPDH, 5=-CACCACTTGGGAGTATTGTGC (forward) and 5=-GGGACAT-CAGTCTCATTCACAG (reverse) for HGF, 5=-CCCTGCTGAG-AAACTCTTCC (forward) and 5=-TTGATGAAGGTGGAGATGGA (reverse) for c-Met, 5=-TGCAAAGACAGTGAGGGAAG (forward) and 5=-AGTGTGCTCGGAGATGTGAG (reverse) for Sp1, 5=-TTG-GCTTCTGCACAGTTAGG (forward) and 5=-GGAAGGACATACT-GCCCACT (reverse) for Sp3, 5=-CGGTCTACACCAGCAACAGT (forward) and 5=-CACATGGAGTCCGAAGTGAG (reverse) for Hes1, 5=-GCAGATGACTGTGGATCACC (forward) and 5=-CCCAAACTC-CGATAGTCCAT (reverse) for Hey1, and 5=-GGATTGCCCACTTC-GAGTAT (forward) and 5=-TATTGCAGCCAAAGCCATAG (reverse) for Jagged1.
Immunoblots. Cells were lysed in ice-cold RIPA buffer plus protease and phosphatase inhibitors (Sigma cocktail), homogenized by shearing through a syringe, clarified by centrifugation, and quantified using bicinchoninic acid protein assay (Thermo Scientific). For tissue lysates, the ␥GT-Cre;Tgfbr2 flox/flox mice, in which recombination was previously confirmed, were injured with a single injection of HgCl 2 (30 mol/kg in saline), and cortical lysates were generated as described previously (10) . For cell and tissue lysates, proteins were separated by SDS-polyacrylamide gel, transferred onto polyvinylidene difluoride or nitrocellulose membranes, blocked in 5% milk or BSA, and incubated with the following primary antibodies: c-Met, phosphorylated c-Met, phosphorylated ERK, phosphorylated Akt, total Akt, and cleaved Notch1 (Cell Signaling), total ERK (Santa Cruz Biotechnology), and E-cadherin (BD Biosciences). GAPDH, focal adhesion kinase (Santa Cruz), and ␣-tubulin (Cell Signaling) were validated as loading controls (data not shown), chosen on the basis of the size of the target protein, and used to control for protein loading. Bands on autoradiography film were quantified using Java-based image-processing software (ImageJ).
Three-dimensional culture assay. PT cells (n ϭ 20,000) were plated in gels containing collagen I and Matrigel as described previously (2, 3) and, once gels solidified, 100 l of complete PT medium (see above) with or without HGF was added. After 5 days, gels were washed, fixed with 4% paraformaldehyde, and either stained with rhodamine-phalloidin (after permeabilization with 0.025% saponin and quenching with 75 mM NH4Cl and 20 mM glycine in PBS with CaCl2 and MgCl2) for confocal imaging or photographed with an inverted microscope and camera, and 10 random tubules were imaged per sample, with branches measured by ImageJ.
Cell migration assay. PT cells (n ϭ 20,000) in serum-free medium were plated on Transwell inserts (8 m) precoated with Matrigel and incubated for 6 h. Cells on top of the membrane (i.e., cells that did not migrate) were removed with a cotton swab, and the bottom was fixed in 4% paraformaldehyde for 45 min. The membrane was stained with 2% crystal violet overnight, images were obtained at ϫ200 magnification with a Nikon Eclipse TE300 inverted microscope (10 randomly chosen fields per sample), and the number of migrated cells was counted and quantified in a blinded fashion. HGF-treated samples were exposed to 40 ng/ml HGF for 24 h before and throughout migration. Cells treated with the ␥-secretase inhibitor (10 M) were pretreated for 3 days (controls received equivalent volumes of DMSO).
Cell morphology. PT cells were plated on Matrigel (BD Biosciences)-coated chamber-well slides in serum-free medium with or without HGF (40 ng/ml) for 24 h and then stained with rhodaminephalloidin. For ␥-secretase studies, PT cells were incubated with the inhibitor or equal amounts of DMSO for 2 days before they were plated on chamber-well slides and stimulated with HGF as described above. Images were obtained using a fluorescence microscope (model BX51, Olympus).
MTS cell proliferation assay. PT cells were plated in 12-well plates, serum-starved overnight, and then treated with HGF for 24 h. To ensure equal numbers of cells, the number of cells was quantified using the CellTiter 96 Aqueous One Solution (Promega) at the time of HGF stimulation and again after 24 h in the presence and absence of HGF.
Isolation of membrane proteins. Subconfluent, serum-starved (overnight) PT cells were placed on ice, washed with PBS (pH 8.0) plus CaCl 2 and MgCl2 (PBS-CM), and incubated with 1 mM EZ-Link Sulfo-NSS-SS-Biotin (Thermo Scientific) in DMEM/F-12 medium supplemented with protease and phosphatase inhibitors (Sigma) for 1 h at 4°C. After PT cells were washed, unbound biotin was quenched by incubation with 0.1% BSA in PBS-CM at 4°C, and cells were washed in PBS-CM, lysed in basic lysis buffer (20 mM Tris·HCl, pH 8, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, and protease and phosphatase inhibitors), scraped, and centrifuged for 15 min at 13,000 rpm at 4°C. Then 50 -60 g of protein per sample were incubated for 16 h with streptavidin-agarose beads (Thermo Scientific) at 4°C, washed, and centrifuged, and the pellet was saved.
Isolation of cytosolic and nuclear proteins. Cytosolic and nuclear fractions were isolated from subconfluent, serum-starved PT cells using a protocol described elsewhere (33) .
Statistics. Student's t-test with unequal variance was used to compare two sets of data; P Ͻ 0.05 was considered statistically significant. Each experiment was repeated three times, and data are shown as means Ϯ SE.
RESULTS

Blocking TGF-␤ signaling in PT cells impairs the response to HGF.
We used PT cells, the target of acute kidney injury, to determine how TGF-␤ signaling affects epithelial responsive- http://ajprenal.physiology.org/ ness to HGF. PT cells, with and without T␤RII (10), were exposed to HGF for 20 min, 2 h, and 6 h. Activation (i.e., phosphorylation) of the HGF receptor c-Met was reduced in T␤RII Ϫ/Ϫ compared with T␤RII flox/flox PT cells (Fig. 1, A and   B) . Also, total expression of the c-Met receptor was reduced in T␤RII Ϫ/Ϫ PT cells (Fig. 1C) , which was not significantly different from the difference in c-Met activation (Fig. 1B) . Although TGF-␤ signaling has been shown to alter HGF (conditional deletion of T␤RII in the PT) and Tgfbr2 flox/flox (floxed control) mice were subjected to HgCl2-induced acute kidney injury and immunoblotted for c-Met expression and phosphorylation with ␣-tubulin as a loading control, and protein expression was quantified. D: lysates of whole cell and membrane preparations (see METHODS) were immunoblotted for c-Met expression with ␣-tubulin, which was used to show the purity of membrane preparations, and ␤1-integrin, which was used as a loading control for membrane expression. PT cells (Fig. 1D) , and minimal HGF protein expression was detected in conditioned medium of PT cells as measured by ELISA (data not shown). Consistent with decreased c-Met phosphorylation, activation of the downstream signaling proteins AKT and ERK in response to HGF was impaired in T␤RII Ϫ/Ϫ PT cells (Fig. 1, E-H) . We stimulated renal cortical fibroblasts in the presence and absence of T␤RII (27) with HGF and observed augmented c-Met activation in T␤RII Ϫ/Ϫ fibroblasts (Fig. 1, I and J) , suggesting that TGF-␤ signaling alters the response to HGF in a cell-specific manner.
T␤RII Ϫ/Ϫ PT cells have reduced c-Met membrane expression and transcript levels. We then examined whether these T␤RII-dependent changes in c-Met expression and phosphorylation were present in PTs in vivo. Expression and phosphorylation of c-Met were significantly reduced in mice lacking T␤RII in PTs (␥GT-Cre;Tgfbr2 flox/flox ) (10) compared with floxed controls after HgCl 2 -induced acute kidney injury (Fig.  2, A-C ), an injury model previously shown to increase HGF transcript levels and activity (14) . As T␤RII-dependent changes in c-Met expression and activation were present in vivo and in vitro, we further investigated how T␤RII alters c-Met expression in vitro. c-Met expression and membrane localization were reduced in T␤RII Ϫ/Ϫ compared with T␤RII flox/flox PT cells (Fig. 2, D-F) . c-Met expression in T␤RII Ϫ/Ϫ PT cells was decreased to a similar extent in whole cell lysates and membrane preparations (47 Ϯ 6% and 45 Ϯ 6%, respectively; Fig. 2, E and F) , suggesting that decreased c-Met expression in T␤RII Ϫ/Ϫ PT cells was not due to increased endocytosis of the receptor. c-Met transcript levels as measured by qPCR were decreased in T␤RII Ϫ/Ϫ PT cells (Fig.  2G) , indicating that the reduced c-Met protein expression is due to transcriptional changes.
To determine whether decreased c-Met expression and activation of T␤RII Ϫ/Ϫ PT cells are due to impaired TGF-␤ signaling, we used a well-characterized inhibitor of ALK5, the T␤RI. ALK5 inhibition significantly reduced HGF activation of c-Met in both cell populations (Fig. 2, H and I) but reduced c-Met transcript levels only in T␤RII flox/flox PT cells (Fig. 2J) . These results imply that the reduced c-Met expression of T␤RII Ϫ/Ϫ PT cells is due to impaired signaling through the TGF-␤ receptors.
We also investigated whether mechanisms other than alteration of c-Met transcription, reduced HGF signaling in T␤RII Ϫ/Ϫ PT cells. We investigated the role of E-cadherin, since this adherens junction protein can inhibit tyrosine kinase growth factor signaling (29) and is suppressed by TGF-␤. Consistent with this, E-cadherin expression and membrane localization were augmented in T␤RII Ϫ/Ϫ PT cells (Fig. 3,  A-C) . Furthermore, the difference in HGF signaling was present only in subconfluent conditions, during which time E- cadherin is suppressed (Fig. 3, D and E) . We disrupted Ecadherin using low-calcium (5 M) medium and confirmed that this augmented c-Met activation in confluent T␤RII flox/flox PT cells (Fig. 3, F and G) . However, low-calcium medium did not alter differences in HGF signaling between T␤RII Ϫ/Ϫ and T␤RII flox/flox PT cells in subconfluent conditions (Fig. 3, H and  I) . Thus, augmented E-cadherin expression does not play a role in reduced HGF signaling in T␤RII Ϫ/Ϫ PT cells. We also investigated whether altered phosphatase activity might account for differences in HGF signaling, as TGF-␤ alters other tyrosine kinase growth factor signaling pathways through phosphatases (35) . As expected, pretreatment of PT cells with Na 3 VO 4 , a tyrosine phosphatase inhibitor, augmented c-Met phosphorylation in response to HGF in T␤RII Ϫ/Ϫ and T␤RII flox/flox PT cells (Fig. 3, J and K) . However, the decreased responsiveness of T␤RII Ϫ/Ϫ PT cells to HGF persisted even with the phosphatase inhibitor (Fig. 3, J  and K) . Taken together, our data show that inhibition of TGF-␤ signaling either genetically or pharmacologically reduces HGF signaling through transcriptional changes in c-Met and not by alteration of E-cadherin expression or phosphatase activity.
Notch signaling mediates reduced HGF signaling of T␤RII
Ϫ/Ϫ PT cells. Our data indicated that the decreased c-Met expression of T␤RII Ϫ/Ϫ PT cells was transcriptionally mediated, so we investigated putative transcription factors that link TGF-␤ signaling and c-Met expression. The transcription factors Sp1 and Sp3 have been shown to regulate c-Met expression (39), but we found no significant differences in their transcript levels between T␤RII flox/flox and T␤RII Ϫ/Ϫ PT cells by qPCR (Fig. 4, A and B) . We then investigated whether the Notch signaling pathway may be involved, since this pathway is a downstream target of TGF-␤ signaling (22) and interacts with the HGF/c-Met pathway in other organs (1, 12) . TGF-␤ has been shown to induce expression of the ligand Jagged1 (22, 28) , and, consistent with this finding, Jagged1 mRNA expression was suppressed in T␤RII Ϫ/Ϫ PT cells (Fig. 4C) . Notch transcriptional targets, Hes1 and Hey1, were also diminished in PT cells lacking T␤RII (Fig. 4, D and E) . Furthermore, cleaved Notch1, an indicator of Notch signaling, was significantly decreased in nuclear isolates of T␤RII Ϫ/Ϫ PT cells (Fig. 4 , F and G). Thus our data indicate that Notch signaling is reduced in T␤RII Ϫ/Ϫ compared with T␤RII flox/flox PT cells. To determine whether the suppressed Notch signaling in T␤RII Ϫ/Ϫ PT cells accounts for its reduced responsiveness to HGF, we inhibited Notch activity using a ␥-secretase inhibitor. As expected, the ␥-secretase inhibitor blocked Notch1 cleavage and Hes1 transcription but also reduced c-Met protein expression and transcription in T␤RII flox/flox PT cells (Fig. 5,  A-E) . Furthermore, addition of the ␥-secretase inhibitor reduced the HGF-induced c-Met activation to levels similar to (Fig. 5, F and G) , implying that the difference in c-Met activation between T␤RII flox/flox and T␤RII Ϫ/Ϫ PT cells is Notch-dependent. T␤RII Ϫ/Ϫ PT cells have reduced biological responses to HGF. We defined the biological significance of reduced HGF signaling in T␤RII Ϫ/Ϫ PT cells by investigating responses to cellular events known to be modulated by HGF signaling. Initially, we explored how TGF-␤ and HGF signaling interact to regulate branching morphogenesis. T␤RII Ϫ/Ϫ PT cells grown in three-dimensional gels (collagen I-Matrigel) had significantly more branching than T␤RII flox/flox PT cells a finding not due to increased tubule length (Fig. 6, A-C) . However, HGF stimulation significantly increased branching in T␤RII flox/flox PT cells (from 5.8 to 10.3 branches per tubule) compared with a minimal change in T␤RII Ϫ/Ϫ PT cells (from 10.1 to 11.8 branches per tubule; Fig. 6, A-C) . HGF is known to induce morphological changes, whereby the cell dedifferentiates and has a more fibroblast-like shape (19, 32) . We observed that T␤RII Ϫ/Ϫ PT cells spread less at baseline than T␤RII flox/flox PT cells (Fig. 6D) . After HGF treatment, T␤RII flox/flox PT cells had a more fibroblast-like appearance, consistent with HGF-induced dedifferentiation, whereas there was little change in the T␤RII Ϫ/Ϫ PT cells (Fig. 6D) . We next defined how HGF altered epithelial migration of PT cells with and without T␤RII on Matrigel-coated Transwell inserts (Fig.  6, E and F) . HGF treatment dramatically increased migration of T␤RII flox/flox , but not T␤RII Ϫ/Ϫ , PT cells (Fig. 6, E and F) . Similarly, HGF promoted more proliferation, and there was a greater increase in the number of HGF-treated T␤RII flox/flox (Ͼ60%) than HGF-treated T␤RII Ϫ/Ϫ (20%) PT cells (Fig. 6G) . Thus, consistent with the decreased signaling in response to HGF, T␤RII Ϫ/Ϫ PT cells had reduced functional responses as well.
␥-Secretase inhibitor abrogated HGF signaling in T␤RII flox/flox PT cells. We then investigated whether inhibiting Notch signaling using the ␥-secretase inhibitor could block the biological responses to HGF in T␤RII flox/flox PT cells. The HGF-induced increase in cell dedifferentiation and lamellopodia formation in T␤RII flox/flox PT cells was reduced by treatment with the ␥-secretase inhibitor, whereas there was little change in the actin cytoskeleton of T␤RII Ϫ/Ϫ PT cells (Fig. 7A) . Similarly, pretreatment with a ␥-secretase inhibitor dramatically reduced T␤RII flox/flox , but not T␤RII Ϫ/Ϫ , PT cell migration (Fig. 7 , B and C). These data suggest that the reduced responsiveness of T␤RII Ϫ/Ϫ PT cells to HGF is mediated through suppressed Notch signaling.
DISCUSSION
TGF-␤ directly alters many epithelial responses to injury but may also modulate cellular events through effects on other key growth factor pathways. We showed that deletion of T␤RII in PTs significantly suppressed HGF signaling and biological responses due to transcriptional reduction of the c-Met receptor. Our data suggest that Notch signaling plays an important role in regulation of the TGF-␤-dependent increase in HGF signaling. Thus our data indicate that the interaction between TGF-␤ and downstream Notch signaling pathways in PT cells is necessary for a full biological response to HGF.
Our finding that TGF-␤ signaling promotes epithelial HGF signaling was somewhat surprising, as others have shown that these growth factors mediate divergent responses to renal injury (20, 24) . These differences may be explained by our data showing that the TGF-␤-dependent changes in HGF signaling were cell type-specific. TGF-␤ signaling inhibited HGF signaling in cortical fibroblasts, which is consistent with other reports showing that blocking T␤RII in mesenchymal cells augments HGF signaling (5) . However, our finding that TGF-␤ does not alter HGF production in epithelial cells contrasts with the suppressive effect of TGF-␤ on HGF synthesis in fibroblasts reported by others (26) , further showing the cell-specific interactions of TGF-␤ and HGF signaling. Although mesenchymal cells are important sources of HGF, injured renal epithelia are considered the most important sites of HGF signaling (41) . Perhaps our finding that epithelial TGF-␤ promotes HGF-dependent signaling is not too surprising, given that both HGF and TGF-␤ promote cell dedifferentiation, spreading, and migration. Thus it is possible that these two growth factors cooperatively interact to regulate cellular responses critical to the injured epithelia.
Deletion of T␤RII in PTs reduced c-Met expression in cells in vitro and in HgCl 2 -injured kidneys. It is unclear if c-Met expression was reduced because TGF-␤ signaling was abrogated or because the kidneys sustained less injury as we previously reported (10) . Since epithelial injury upregulates c-Met, reduced injury could also reduce c-Met expression; however, our in vitro data suggest that impaired TGF-␤ signaling contributes to decreased c-Met expression. Our finding that TGF-␤ augmented HGF signaling through a transcriptional increase in the c-Met receptor is consistent with the finding of Zhang et al. (40) that c-Met transcription is upregulated by exogenous TGF-␤ in human PT cells (40) . However, this earlier study showed that the transcription factor Sp1 was critical to c-Met transcription induced by exogenous TGF-␤1 (40), while we showed no difference in levels of Sp1 expression between T␤RII flox/flox and T␤RII Ϫ/Ϫ PT cells. Differences in the cells used (conditionally immortalized murine PT cells vs. immortalized human PT cells) may account for discrepant mechanisms, but the relationship between renal epithelial TGF-␤ and HGF appears conserved between species.
To confirm that the reduced HGF signaling in T␤RII Ϫ/Ϫ PT cells was due to suppressed TGF-␤ signaling, we pharmacologically inhibited the T␤RI using the well-established ALK5 inhibitor. This inhibitor reduced responsiveness to HGF and c-Met expression in the T␤RII flox/flox PT cells, but also reduced responsiveness to HGF in T␤RII Ϫ/Ϫ PT cells without significantly changing c-Met expression. TGF-␤-independent ligands (e.g., activins) may activate ALK5 in a T␤RII-independent manner. Our data suggest that these TGF-␤ ligand-independent signaling pathways also alter HGF signaling, but not through c-Met transcription.
Our studies also illustrate how deletion of T␤RII from PTs fundamentally changes the cells: reducing cell spreading, altering actin cytoskeleton, and augmenting E-cadherin expression. Some of these changes are consistent with our previous findings that deletion of T␤RII in collecting duct epithelia altered stress fiber formation and augmented Rho GTPase activity (9) . Although many studies have focused on how excessive TGF-␤ signaling dramatically alters the epithelial cytoskeleton as part of an epithelial-to-mesenchymal transition, our results suggest that even basal TGF-␤ signaling is integral to epithelial cell structure and organization.
Our data convincingly show that TGF-␤ signaling in PT cells increases Notch activity, which is consistent with previous reports showing that exogenous TGF-␤1 augments epithelial Notch signaling (22, 34, 36, 37) . The mechanism whereby TGF-␤ signaling upregulates Notch activity was beyond the scope of this study, but our results showing decreased Jagged1 transcription in T␤RII Ϫ/Ϫ PT cells are consistent with other studies indicating that TGF-␤ increases Notch signaling through transcriptional upregulation of Jagged1 (22, 28, 37) . Others have shown that Smad3 is critical to TGF-␤-induced Jagged1/Notch signaling in renal epithelia (37) . Taken together with earlier studies showing that TGF-␤ induced c-Met expression through Smads (40) , it is possible that Smad-dependent induction of Jagged1 augments Notch activity, which is key to TGF-␤-dependent c-Met expression and augmented HGF signaling (Fig. 8) . While little is known about Notch interactions with c-Met in the kidney, there is evidence of cross talk between c-Met and Notch signaling pathways in cancer biology (38) . However, there are conflicting results regarding how Notch affects c-Met transcription: suppression of Notch1 reduced c-Met expression in one study, but constitutively active Notch repressed c-Met transcription in another (1, 31) . To block the effects of Notch, we used a ␥-secretase inhibitor, which prevented Notch cleavage in our studies and has been widely used by others to inhibit Notch signaling (4, 6, 34) . However, ␥-secretase inhibitors are not specific for Notch signaling, and it is possible that another ␥-secretase target mediates TGF-␤-dependent c-Met transcription.
The interactions between TGF-␤ and HGF in our studies were shown to be biologically relevant, as T␤RII Ϫ/Ϫ PT cells had impaired HGF-mediated cellular responses. Furthermore, we showed that TGF-␤ enhances the response to HGF through Notch signaling, as both HGF-dependent morphological changes and migration in T␤RII flox/flox PT cells were blocked with the ␥-secretase inhibitor. The signaling interactions among TGF-␤, HGF, and Notch pathways in epithelial cells have not been well studied, but each of these pathways has been shown to be upregulated in tubular injury and to promote epithelial dedifferentiation. In the injured renal epithelium, coordinated signaling among growth factor pathways that control differentiation may be important to allow regeneration after renal injury.
In conclusion, this study demonstrates biologically significant interactions between TGF-␤ and HGF signaling pathways in PT epithelial cells. In addition, we show that Notch signaling plays an important role in regulation of these interactions. These findings suggest that intact epithelial TGF-␤ signaling is necessary for a full biological response to HGF. Furthermore, TGF-␤ signaling alters epithelial cell behavior not only by direct effects, but also by changing how these cells respond to other growth factors.
